Singlera Genomics is a developer of 'liquid biopsy' analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA. Singlera's PanSeer assay can detect cancer four years before conventional diagnosis through a sophisticated but easily implemented targeted methylation assay and efficient bioinformatics analysis. Singlera's ColonES assay has high sensitivity (over 97% for CRC Stg I and 91% for advanced adenomas) and very high specificity (99% for healthy individuals). Currently pre-commercial, Singlera welcomes contact from potential collaborators to bring this revolutionary technology to market.